Evidence map›Paper›PMID 36146648›Full record

ArticleViruses2022

Risk of Pulmonary Fibrosis and Persistent Symptoms Post-COVID-19 in a Cohort of Outpatient Health Workers.

Rosario Fernández-Plata, Anjarath-Lorena Higuera-Iglesias, Luz María Torres-Espíndola, Arnoldo Aquino-Gálvez, Rafael Velázquez Cruz, Ángel Camarena, Jaime Chávez Alderete, Javier Romo García, Noé Alvarado-Vásquez, David Martínez Briseño and 2 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Rosario Fernández-PlataDepartment of Epidemiology and Statistics, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Tlalpan 4502, Mexico City 14080, Mexico.ORCID 0000-0002-2971-0845
Anjarath-Lorena Higuera-IglesiasDepartment of Epidemiology and Statistics, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Tlalpan 4502, Mexico City 14080, Mexico.
Luz María Torres-EspíndolaLaboratory of Pharmacology, National Institute of Pediatrics, Insurgentes Sur 3700, Mexico City 04530, México.
Arnoldo Aquino-GálvezLaboratory of Molecular Biology of Emerging Diseases and COPD, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Tlalpan 4502, Mexico City 14080, Mexico.ORCID 0000-0002-2869-5516
Rafael Velázquez CruzGenomics of Bone Metabolism Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City 14610, Mexico.ORCID 0000-0003-4515-0777
Ángel CamarenaLaboratory of HLA, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Tlalpan 4502, Mexico City 14080, Mexico.
Jaime Chávez AldereteDepartment of Bronchial Hyperreactivity, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Tlalpan 4502, Mexico City 14080, Mexico.ORCID 0000-0001-7472-2936
Javier Romo GarcíaDepartment of Epidemiology and Statistics, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Tlalpan 4502, Mexico City 14080, Mexico.
Noé Alvarado-VásquezDepartment of Biochemistry, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Tlalpan 4502, Mexico City 14080, Mexico.ORCID 0000-0001-6465-9961
David Martínez BriseñoDepartment of Epidemiology and Statistics, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Tlalpan 4502, Mexico City 14080, Mexico.ORCID 0000-0002-8613-2658
Manuel Castillejos-LópezDepartment of Epidemiology and Statistics, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Tlalpan 4502, Mexico City 14080, Mexico.ORCID 0000-0001-8689-9755
Research Working Group
National Institute of Genomic Medicine · MXUniversidad Insurgentes · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Infection by SARS-CoV-2 has been associated with multiple symptoms; however, still, little is known about persistent symptoms and their probable association with the risk of developing pulmonary fibrosis in patients post-COVID-19. Methods: A longitudinal prospective study on health workers infected by SARS-CoV-2 was conducted. In this work, signs and symptoms were recorded of 149 health workers with a positive PCR test for SARS-CoV-2 at the beginning of the diagnosis, during the active infection, and during post-COVID-19 follow-up. The McNemar chi-square test was used to compare the proportions and percentages of symptoms between the baseline and each follow-up period. Results: The signs and symptoms after follow-up were cardiorespiratory, neurological, and inflammatory. Gastrointestinal symptoms were unusual at the disease onset, but unexpectedly, their frequency was higher in the post-infection stage. The multivariate analysis showed that pneumonia (HR 2.4, IC95%: 1.5−3.8, p < 0.001) and positive PCR tests still after four weeks (HR 5.3, IC95%: 2.3-12.3, p < 0.001) were factors associated with the diagnosis of post-COVID-19 pulmonary fibrosis in this study group. Conclusions: Our results showed that pneumonia and virus infection persistence were risk factors for developing pulmonary fibrosis post-COVID-19, after months of initial infection.

Indexed as

COVID-19Pulmonary FibrosisHumansOutpatientsProspective StudiesSARS-CoV-2outpatientpersistence of symptomspost-COVID-19pulmonary fibrosisSARS-CoV-2

Identifiers

PMID36146648
PMCPMC9504101
OpenAlexW4293169000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.